Redirecting to https://www.manilatimes.net/2025/08/19/tmt-newswire/pr-newswire/nature-medicine-publishes-results-of-phase-ii-study-of-sacituzumab-tirumotecan-plus-tagitanlimab-as-first-line-therapy-for-nsclc/2170225